High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

(2021) Maximilian Stahl et al.   Blood Advances

Azacitidine and Durvalumab in First-line Treatment of Elderly Patients With Acute Myeloid Leukemia

(2021) Amer M. Zeidan et al.   Blood Advances

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Study of Midostaurin and 5-Azacitidine for Untreated FLT3 Wild Type Elderly and Unfit Acute Myelogenous Leukemia Patients

(2019) Benjamin K. Tomlinson et al.   Clinical Lymphoma Myeloma & Leukemia

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

(2018) Naval Daver et al.   Cancer Discovery

A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients

(2015) Brenda W. Cooper et al.   Clinical Lymphoma Myeloma & Leukemia

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

(2013) Jie Jin et al.   LANCET ONCOLOGY